⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374261 | 0.82 | HRH1 (0.38) | — | |
| SCHEMBL3150690 | 0.82 | LOXL2 (0.33) | — | |
| SCHEMBL7982137 | 0.78 | — | — | |
| SCHEMBL1660131 | 0.76 | — | — | |
| SCHEMBL1661258 | 0.76 | — | — | |
| SCHEMBL4536920 | 0.76 | — | — | |
| SCHEMBL1370741 | 0.76 | — | — | |
| SCHEMBL28242954 | 0.76 | — | — | |
| SCHEMBL14399500 | 0.76 | — | — | |
| SCHEMBL1762059 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676486-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025090870-A1 | INFIGRATINIB AND METABOLITES THEREOF FOR USE IN METHODS OF TREATING SKELETAL DISORDERS | QED THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250101002-A1 | DEUTERATED INFIGRATINIB COMPOUNDS | Ferro Therapeutics, Inc. | 2025-03-27 | — | — | US | disclosed |
| WO-2024186882-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024093681-A1 | USE OF INFIGRATINIB IN TREATING GASTRIC CANCER AND ADENOCARCINOMA | QED医药股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-117982507-A | Use of inflictinib in the treatment of gastric and adenocarcinoma | QED医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | CALCILYTIX THERAPEUTICS INC. | 2024-01-11 | — | — | US | disclosed |
| EP-4262774-A1 | METHODS OF TREATING ACHONDROPLASIA | QED Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11787771-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| CN-101035769-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |